Other Label Information 16 HOW SUPPLIED/STORAGE AND HANDLING Product: 50090-5824 NDC: 50090-5824-0 .5 mL in a SYRINGE, PLASTIC / 4 in a CARTON WEGOVY (SEMAGLUTIDE) INJECTION, SOLUTION Label Images# DailyMed RxNorm Mappings# DailyMed Pharmacologic Classes# DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# DailyMed Package Descriptions# DailyMed Dashboard NDC Coverage# DailyMed Billing Units# Products# WEGOVY NDC Codes# Ingredients# Complete SPL Sections# WARNING: RISK OF THYROID C-CELL TUMORS Boxed Warning section In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
[ \- Link Opens in New Tab]( 09
One section says 12 to 16 weeks at a therapeutic dose, another cites 12 to 20 weeks, and the eligibility section says 16 to 24 weeks, while the underlying trial figure it quotes is measured over 68 weeks
Additional complications reported include acute kidney injury caused by dehydration from severe gastrointestinal issues such as vomiting and diarrhea
The growing interest in MOTS-c comes from its potential to enhance exercise performance, fat loss, and anti-aging outcomes
Candidate genes for alcohol preference identified by expression profiling in alcohol-preferring and -nonpreferring reciprocal congenic rats